Alebund Pharmaceuticals (Jiangsu) Limited
禮邦醫藥(江蘇)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 09637)

VOLUNTARY ANNOUNCEMENT
INVESTIGATIONAL NEW DRUG APPLICATION FOR AP308 FOR THE TREATMENT OF IgA NEPHROPATHY CLEARED BY THE U.S. FOOD AND DRUG ADMINISTRATION

This announcement is made by Alebund Pharmaceuticals (Jiangsu) Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business development of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the Company recently received clearance of its Investigational New Drug ("**IND**") application for AP308, a first-in-class engineered recombinant IgA protease, from the U.S. Food and Drug Administration (the "**FDA**") to initiate a first-in-human clinical trial of AP308 for the treatment of IgA nephropathy ("**IgAN**"). To the Company's knowledge, AP308 is the first IgA protease-based drug candidate for IgAN to enter clinical development. The Company plans to initiate the clinical trial in the near term.

ABOUT AP308

AP308 is a first-in-class engineered recombinant IgA protease aiming for the functional cure of IgAN. The drug is developed based on an IgA protease derived from *Thomasclavelia ramosa*, a human commensal bacterium, and can cleave IgA1, galactose-deficient IgA1 (Gd-IgA1), polymeric IgA and IgA immune complexes, and directly clears IgA immune complexes and complement C3 already deposited in the glomeruli; in preclinical studies, it acted within minutes without affecting other immunoglobulins such as IgG and IgM. In January 2022, Alebund worked together with Peking University First Hospital ("**PUFH**") on developing IgA proteases into potential IgAN treatment and entered into a license agreement with PUFH. The Company has since developed and nominated AP308 as a drug candidate using its proprietary Long-Acting Protease Engineering Platform. The platform displays excellent stability and developability, extends circulating half-life, reduces renal clearance, and lowers immunogenicity while preserving the protease's potent cleavage activity against IgA1, thereby enabling long-acting, low-frequency dosing. The Company holds the global rights to develop, manufacture, and commercialize AP308.

PRECLINICAL DATA

In a humanized mouse model of IgAN, once-weekly subcutaneous dosing of AP308 over an eight-week treatment period reduced circulating human IgA and IgA immune complexes by approximately 80% relative to controls; at the end of treatment, histological examination confirmed that glomerular IgA deposits were almost completely cleared, proteinuria decreased significantly, and kidney pathology improved markedly, while repeated dosing produced no signals of liver or kidney toxicity and no significant increase in anti-drug antibody titers. In a separate paired pre- and post-treatment design, a single dose completely cleared pre-existing chronic glomerular IgA and complement C3 deposits within seven days. These preclinical results were published in May 2026 in Kidney International, the official journal of the International Society of Nephrology (Shen X, et al. 2026;110:463-476; available at: https://doi.org/10.1016/j.kint.2026.04.020).

IgA NEPHROPATHY

IgAN is the most common primary glomerulonephritis worldwide. It is characterized by the deposition of IgA-containing immune complexes in the glomeruli, which leads to inflammation and progressive kidney damage. Long-term cohort studies in China and the United Kingdom show that, under current treatment strategies, median kidney survival is approximately 11 to 12 years and most patients progress to end-stage renal disease within 10 to 15 years of diagnosis, with approximately 60% of patients in the Chinese cohort reaching end-stage renal disease within 15 years. According to China Insights Consultancy, there were approximately 9.5 million IgAN patients globally in 2025, including approximately 5.1 million in China — more than half of the global total and the largest IgAN patient population in the world. However, strategies to directly clear IgA immune complexes already deposited in the kidney remain to be further explored. By directly cleaving and clearing pathogenic IgA and IgA immune complexes that have already been deposited in the glomeruli, AP308 represents a differentiated therapeutic approach with the potential to address this unmet medical need in the treatment of IgAN.

By order of the Board
Alebund Pharmaceuticals (Jiangsu) Limited
Dr. Gavin Guoyao Xia
Chairman of the Board, executive Director and Chief Executive Officer

Hong Kong, September 8, 2026

As of the date of this announcement, the Board comprises (i) Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading as executive Directors; (ii) Dr. Lu An as a non-executive Director; and (iii) Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai as independent non-executive Directors.